- Lobbying
- Lobbying by Pernix Therapeutics
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Dave Boyer | Sp Asst Pres LA, Asst Comm Leg, FDA, Sp Asst to Sec HHS, Con Asst, Off of WH Liaison DoD, Con Asst, Off of Sec Lab See prior filing |
Ryan Long | LC Rep Norwood; LA & LD Rep Barton;Prof. Staff, Csel, & Chief Csel Hse E&C Ctme See prior filing |
Brent Del Monte | LA/LD Rep. Tom Bliley; Counsel House E&C Committee See prior filing |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Provide advice, counsel, and as appropriate direct advocacy services related to public policies impacting the biopharmaceutical industry generally, and Pernixs priorities and product portfolio specifically..
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate